

Mail Requests To: Cigna

8455 University Place # HQ2L-04

St. Louis, MO 63121

Fax Requests To: (866) 845-7267 Request By Phone: (877) 813-5595

## Buprenorphine SL tabs, Buprenorphine/Naloxone SL tabs, Suboxone Film and Zubsolv tabs Coverage Determination (FOR PROVIDER USE ONLY)

MEMBER INFORMATION REQUIRED (Please Write Legibly)					
Customer Name:		Customer ID:			
Customer DOB:		Customer Address:			
Phone (Home):		Phone (Cell):	Phone (Cell):		
PROVIDER INFORMATION I License Number: DEA Number:		REQUIRED (Please V	REQUIRED (Please Write Legibly)    NPI Number:		
License Number:	DEA Number:		NPI Number:		
Provider Name:		Provider Address:			
Provider Phone:		Provider Fax:			
Provider Specialty:		Office Contact Name:			
DRUG & PRES	SCRIPTION INFORMAT	ION REQUIRED (Pleas	se Write Le	gibly)	
Drug Name:		Dosage:			
Frequency:		Quantity:	Days Supply:	Refills:	
- D- N-t Out-titute Discusses A		Diagon about whathey this is		ion on the comment of the continue of the cont	
□ Do Not Substitute-Dispense A	s written	Please check whether this is a new medication or therapy continuation			
		☐ New Medication	ion	☐ Continuation	
	If you have checked "Continuation",				
Provide Start Date>					
	SELECT DI	AGNOSIS			
□ Opioid Dependence					
List Diagnosis/ICD-10 Code(s):					



Mail Requests To: Cigna

8455 University Place # HQ2L-04

St. Louis, MO 63121

Fax Requests To: (866) 845-7267 Request By Phone: (877) 813-5595

## Buprenorphine SL tabs, Buprenorphine/Naloxone SL tabs, Suboxone Film and Zubsolv tabs Coverage Determination (FOR PROVIDER USE ONLY)

ATTENTION: FAILURE TO PROVIDE CLINICAL INFORMATION SUPPORTING RATIONALE MAY RESULT IN THIS REQUEST BEING DENIED, OR AN ADDITIONAL OUTREACH TO OBTAIN MISSING CLINICAL INFORMATION.

APPROVALS FOR BUPRENORPHINE SUBLINGUAL TABLETS ARE I		
BUPRENORPHINE INDUCTION THERAPY, FOLLOWED BY MAINTEI		
BUPRENORPHINE/NALOXONE UNLESS THE CUSTOMER MEETS O	NE OF THE FOLLOWI	NG CRITERIA:
Is the customer pregnant?	□ YES	□ NO
Has the customer experienced a hypersensitivity reaction to naloxone?	□ YES	□ NO
If the customer is unable to meet the criteria required for the requested medication, please pro exception should be made:	ovide a clinical explanation as	to why an
Is the request for an inpatient that is awaiting discharge?	□ YES	□ NO
TABS HAVE A QUANTITY LIMIT OF 90 PER 30 DAYS. IF A GREAT ANSWER THE QUESTIONS BE	LOW.	
Has the customer tried and failed a lower dose (please document below)?	☐ YES	□ NO
If lower dosing was not tried, please provide clinical explanation as to why dosing within the qu negatively impact medication compliance.	antity limit would be ineffectiv	e, cause adverse effect or
Request for expedited review [24 hours]. By checking this box, I certify that applying the 7 standard review time frame may seriously jeopardize the life or health of the Customer or to		aximum function
Provider Signature:	Date:	

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Arizona, Inc., Cigna HealthCare of St. Louis, Inc., HealthSpring Life & Health Insurance Company, Inc., HealthSpring of Florida, Inc., Bravo Health Mid-Atlantic, Inc., and Bravo Health Pennsylvania, Inc. The Cigna name, Iogos, and other Cigna marks are owned by Cigna Intellectual Property, Inc. Cigna-HealthSpring is contracted with Medicare for PDP plans, HMO and PPO plans in select states, and with select State Medicaid programs. Enrollment in Cigna-HealthSpring depends on contract renewal.